Evidence map›Paper›PMID 35609012›Full record

ArticleVox sanguinis2022

Risk of variant Creutzfeldt-Jakob disease transmission by blood transfusion in Australia.

Hamish McManus, Clive R Seed, Veronica C Hoad, Philip Kiely, John M Kaldor, Claire E Styles, Hong Yang, Matthew Law, Iain B Gosbell

Open access · greenAbstract read
In one paragraph

Article in Vox sanguinis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Challenges for Plasma-Derived Medicinal Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Hamish McManusKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7264-8848
Clive R SeedAustralian Red Cross Lifeblood, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0234-4507
Veronica C HoadAustralian Red Cross Lifeblood, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7827-3661
Philip KielyAustralian Red Cross Lifeblood, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-2849-7122
John M KaldorKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Claire E StylesAustralian Red Cross Lifeblood, Melbourne, Victoria, Australia.
Hong YangUS Food and Drug Administration, Rockville, Maryland, USA.
Matthew LawKirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Iain B GosbellAustralian Red Cross Lifeblood, Melbourne, Victoria, Australia.
Australian Red Cross Lifeblood · AUUNSW Sydney · AUUnited States Food and Drug Administration · US

Funding

National Health and Medical Research Council APP1151959
6 · The paper itself

Abstract

BACKGROUND AND

objectivesMost of the 233 worldwide cases of variant Creutzfeldt-Jakob disease (vCJD) have been reported in the United Kingdom and 3 have been associated with transfusion-transmission. To mitigate the potential vCJD risk to blood safety, Australian Red Cross Lifeblood imposes restrictions on blood donation from people with prior residency in, or extended travel to, the United Kingdom during the risk period 1980-1996. We have modified a previously published methodology to estimate the transfusion-transmission risk of vCJD associated with fresh component transfusion in Australia if the UK residence deferral was removed. MATERIALS AND

methodsThe prevalence of current pre-symptomatic vCJD infection in the United Kingdom by age at infection and genotype was estimated based on risk of exposure to the bovine spongiform encephalopathy agent for the period 1980-1996. These results were used to estimate the age-specific prevalence of undiagnosed, pre-symptomatic vCJD in the Australian population in the current year due to prior UK residency or travel. The primary model outputs were the 2020 vCJD risks/unit of vCJD contamination, transfusion-transmission (infections) and clinical cases.

resultsThe overall (prior UK residency in and travel to United Kingdom, 1980-1996) mean risk of contamination per unit was 1 in 29,900,000. The risks of resulting vCJD transmission (infection) and clinical case were 1 in 389,000,000 and 1 in 1,450,000,000, respectively.

conclusionOur modelling suggests that removing the Lifeblood donation deferral for travel to, or UK residence, would result in virtually no increased risk of vCJD transfusion-transmission and would be a safe and effective strategy for increasing the donor base.

Indexed as

Creutzfeldt-Jakob SyndromeAnimalsAustraliaBlood DonorsBlood TransfusionCattleHumansUnited Kingdomblood transfusionrisktransfusion-transmissionvariant Creutzfeldt-Jakob diseasevCJD

Identifiers

PMID35609012
PMCPMC9544957
OpenAlexW4281390859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.